retatrutide glp-1 receptor agonist Retatrutide, a GIP, and glucagon agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA Retatrutide in Johnson County -

Accumulation of cytosolic dsDNA contributes to fibroblast-like synoviocytes-mediated rheumatoid arthritis synovial inflammation

"There is growing evidence that the drugs have a meaningful impact on consumer behavior and spending on groceries and restaurants," Morgan Stanley analysts said in the survey

Faika, M

How to Market Your GLP-1 Program Building a successful direct-to-consumer GLP-1 prescription program takes more than clinical access and pharmacy coordination

Remember to report any suspected side effects to the MHRA through the Yellow Card Scheme

Innovent has also entered into more than 30 strategic collaborations with Eli Lilly, Roche, Sanofi, Adimab, Incyte, MD Anderson Cancer Center and other international partners